BioArctic Valuation
Is BIOA B undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of BIOA B when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: BIOA B (SEK165) is trading below our estimate of fair value (SEK550.75)
Significantly Below Fair Value: BIOA B is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for BIOA B?
Other financial metrics that can be useful for relative valuation.
What is BIOA B's n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | SEK 14.58b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 47.3x |
Enterprise Value/EBITDA | -190.2x |
PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does BIOA B's PS Ratio compare to its peers?
Company | Forward PS | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 15.2x | ||
BONEX Bonesupport Holding | 26.5x | 33.8% | SEK 19.5b |
BIOG B BioGaia | 8.4x | 12.2% | SEK 11.5b |
VITR Vitrolife | 9.3x | 7.8% | SEK 32.8b |
HNSA Hansa Biopharma | 16.6x | 44.2% | SEK 2.7b |
BIOA B BioArctic | 48.7x | 42.4% | SEK 14.6b |
Price-To-Sales vs Peers: BIOA B is expensive based on its Price-To-Sales Ratio (48.7x) compared to the peer average (15.2x).
Price to Earnings Ratio vs Industry
How does BIOA B's PE Ratio compare vs other companies in the SE Biotechs Industry?
Price-To-Sales vs Industry: BIOA B is expensive based on its Price-To-Sales Ratio (48.7x) compared to the Swedish Biotechs industry average (11.9x).
Price to Sales Ratio vs Fair Ratio
What is BIOA B's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PS Ratio | 48.7x |
Fair PS Ratio | 13.8x |
Price-To-Sales vs Fair Ratio: BIOA B is expensive based on its Price-To-Sales Ratio (48.7x) compared to the estimated Fair Price-To-Sales Ratio (13.8x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
---|---|---|---|---|---|---|---|
Current | SEK 163.30 | SEK 290.60 +78.0% | 8.8% | SEK 340.00 | SEK 270.00 | n/a | 5 |
Sep ’25 | SEK 166.50 | SEK 290.60 +74.5% | 8.8% | SEK 340.00 | SEK 270.00 | n/a | 5 |
Aug ’25 | SEK 166.50 | SEK 336.40 +102.0% | 8.1% | SEK 370.00 | SEK 290.00 | n/a | 5 |
Jul ’25 | SEK 235.40 | SEK 368.00 +56.3% | 11.8% | SEK 450.00 | SEK 325.00 | n/a | 5 |
Jun ’25 | SEK 242.60 | SEK 368.00 +51.7% | 11.8% | SEK 450.00 | SEK 325.00 | n/a | 5 |
May ’25 | SEK 195.00 | SEK 366.20 +87.8% | 12.2% | SEK 450.00 | SEK 325.00 | n/a | 5 |
Apr ’25 | SEK 215.40 | SEK 366.20 +70.0% | 12.2% | SEK 450.00 | SEK 325.00 | n/a | 5 |
Mar ’25 | SEK 219.20 | SEK 365.20 +66.6% | 12.2% | SEK 450.00 | SEK 325.00 | n/a | 5 |
Feb ’25 | SEK 218.00 | SEK 376.40 +72.7% | 8.8% | SEK 440.00 | SEK 342.00 | n/a | 5 |
Jan ’25 | SEK 267.80 | SEK 369.33 +37.9% | 11.1% | SEK 450.00 | SEK 312.00 | n/a | 6 |
Dec ’24 | SEK 231.80 | SEK 372.40 +60.7% | 11.9% | SEK 450.00 | SEK 312.00 | n/a | 5 |
Nov ’24 | SEK 221.20 | SEK 392.00 +77.2% | 8.8% | SEK 450.00 | SEK 356.00 | n/a | 5 |
Oct ’24 | SEK 283.00 | SEK 392.00 +38.5% | 8.8% | SEK 450.00 | SEK 356.00 | n/a | 5 |
Sep ’24 | SEK 314.40 | SEK 392.00 +24.7% | 8.8% | SEK 450.00 | SEK 356.00 | SEK 166.50 | 5 |
Aug ’24 | SEK 298.80 | SEK 392.00 +31.2% | 8.8% | SEK 450.00 | SEK 356.00 | SEK 166.50 | 5 |
Jul ’24 | SEK 282.00 | SEK 395.20 +40.1% | 10.6% | SEK 460.00 | SEK 356.00 | SEK 235.40 | 5 |
Jun ’24 | SEK 326.20 | SEK 395.20 +21.2% | 10.6% | SEK 460.00 | SEK 356.00 | SEK 242.60 | 5 |
May ’24 | SEK 264.40 | SEK 395.20 +49.5% | 10.6% | SEK 460.00 | SEK 356.00 | SEK 195.00 | 5 |
Apr ’24 | SEK 251.40 | SEK 399.20 +58.8% | 9.9% | SEK 460.00 | SEK 356.00 | SEK 215.40 | 5 |
Mar ’24 | SEK 298.20 | SEK 399.20 +33.9% | 9.9% | SEK 460.00 | SEK 356.00 | SEK 219.20 | 5 |
Feb ’24 | SEK 311.40 | SEK 367.80 +18.1% | 22.5% | SEK 460.00 | SEK 220.00 | SEK 218.00 | 5 |
Jan ’24 | SEK 272.00 | SEK 356.20 +31.0% | 23.3% | SEK 460.00 | SEK 220.00 | SEK 267.80 | 5 |
Dec ’23 | SEK 292.20 | SEK 356.20 +21.9% | 23.3% | SEK 460.00 | SEK 220.00 | SEK 231.80 | 5 |
Nov ’23 | SEK 232.60 | SEK 356.25 +53.2% | 26.0% | SEK 460.00 | SEK 220.00 | SEK 221.20 | 4 |
Oct ’23 | SEK 271.60 | SEK 281.25 +3.6% | 36.7% | SEK 460.00 | SEK 220.00 | SEK 283.00 | 4 |
Sep ’23 | SEK 92.80 | SEK 266.33 +187.0% | 23.3% | SEK 354.00 | SEK 220.00 | SEK 314.40 | 3 |
Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.